Syntagon says China office will reduce sourcing costs

pharmafile | June 3, 2009 | News story | Research and Development |  CRO, Syntagon 

Related Content

Lilly secures conditional MHRA approval for new blood cancer treatment

Crown Bioscience opens new US model development centre

Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …

From molecule to market and beyond: Uniphar announces extended global commercialization platform

22 October 2024 – Dublin, Ireland – Healthcare services business, Uniphar, has developed its full-service …

Science image

Drug development contracts: can lessons be learned from healthcare delivery?

There is a very good question to ask at the beginning of every project: “What …

The Gateway to Local Adoption Series

Latest content